Text Size

0.05 mg Versus 0.1 mg Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy

This study is currently recruiting participants.
Verified September 2011 by Mahidol University
Sponsor:
Information provided by (Responsible Party):
Sirilak Suksompong, Mahidol University
ClinicalTrials.gov Identifier:
NCT01080911
First received: March 3, 2010
Last updated: September 5, 2011
Last verified: September 2011
History of Changes
  Purpose

This study aims to compare the effect of spinal morphine between the dose 0.05 mg and 0.1 mg on the amount of morphine during the first 24 hours postoperative.


Condition Intervention Phase
Pain
 Drug: Morphine
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: 0.05 vs. 0.1 Milligram Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy With/Without Anterior and Posterior Vaginoplasty

Resource links provided by NLM:

MedlinePlus related topics: Hysterectomy
U.S. FDA Resources

Further study details as provided by Mahidol University:

Primary Outcome Measures:
  • the amount of 24 hours morphine [ Time Frame: 24 hour ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 72
Study Start Date: March 2010
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: spinal morphine 0.05 mg
spinal morphine 0.05 mg plus 0.5% heavy marcaine 3.5 ml
 Drug: Morphine
spinal morphine 0.05 mg
Other Name: opioid
Active Comparator: spinal morphine 0.1 mg
spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
 Drug: Morphine
spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
Other Name: Opioid

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female ASA 1-3
  • Undergoing vaginal hysterectomy with/without anterior and posterior vaginoplasty
  • Can operate PCA device

Exclusion Criteria:

  • History of allergy to the study drugs
  • History of bleeding tendency
  • History of infection at the back
  • Patient refuse to have spinal anesthesia
  • History of CAD or CVD
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01080911

Contacts
Contact: Sirilak Suksompong, MD 6624113256 sisuk@mahidol.ac.th

Locations
Thailand
Faculty of Medicine, Siriraj Hospital, mahidol University Recruiting
Bangkok, Thailand, 10700
Contact: Sirilak Suksompong, MD     6604113256     sisuk@mahidol.ac.th    
Principal Investigator: Sirilak Suksompong, MD            
Sponsors and Collaborators
Mahidol University
Investigators
Principal Investigator: Sirilak Suksompong, MD Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University
  More Information

No publications provided

Responsible Party: Sirilak Suksompong, Associate Professor, Mahidol University
ClinicalTrials.gov Identifier: NCT01080911     History of Changes
Other Study ID Numbers: Si073/2010
Study First Received: March 3, 2010
Last Updated: September 5, 2011
Health Authority: Thailand: Ethical Committee

Keywords provided by Mahidol University:
Spinal morphine
Vaginal hysterectomy

Additional relevant MeSH terms:
Morphine
Analgesics, Opioid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
 Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Narcotics

ClinicalTrials.gov processed this record on May 23, 2013